Free tool
FAERS Monitor: Nuedexta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021879 or its brand name (Nuedexta, Dextromethorphan Hydrobromide, Quinidine Sulfate). Reports on generic versions are filed under their own applications.
Reports
3,631
Serious
1,230
34% of reports
Hospitalization
502
Death reported
282
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fall208
- off label use208
- product use in unapproved indication195
- death192
- drug ineffective192
- dizziness169
- therapy interrupted161
- fatigue145
- diarrhoea135
- nausea111
- somnolence104
- dysphagia102
- inability to afford medication101
- gait disturbance97
- condition aggravated96
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 16 |
| 2012 | 33 |
| 2013 | 38 |
| 2014 | 73 |
| 2015 | 559 |
| 2016 | 518 |
| 2017 | 414 |
| 2018 | 368 |
| 2019 | 331 |
| 2020 | 244 |
| 2021 | 190 |
| 2022 | 122 |
| 2023 | 212 |
| 2024 | 264 |
| 2025 | 201 |
| 2026 | 48 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,528 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| inability to afford medicationSignal | 101 | 59.5 | 49.0 | 5,696 |
| therapy interruptedSignal | 161 | 13.1 | 11.2 | 1,786 |
| dysphagiaSignal | 102 | 6.2 | 5.1 | 444 |
| product use in unapproved indicationSignal | 195 | 4.6 | 4.0 | 544 |
| fallSignal | 208 | 3.6 | 3.2 | 398 |
| somnolenceSignal | 104 | 3.0 | 2.5 | 137 |
| gait disturbanceSignal | 97 | 2.9 | 2.4 | 123 |
| dizziness | 169 | 2.0 | 1.7 | 81 |
| condition aggravated | 96 | 1.8 | 1.5 | 36 |
| off label use | 208 | 1.4 | 1.2 | 22 |
| death | 192 | 1.3 | 1.1 | 13 |
| diarrhoea | 135 | 1.2 | 1.0 | 5 |
| fatigue | 145 | 1.1 | 0.9 | 1 |
| drug ineffective | 192 | 0.8 | 0.7 | 6 |
| nausea | 111 | 0.8 | 0.7 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.